Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 100 entries
View as:

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Phase: N/A Priority: Normal
NCT ID: NCT05297240 Org: User:
Start: 03/24/22 End: 12/31/22 Due: 12/31/23

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Phase: N/A Priority: Normal
NCT ID: NCT00408278 Org: User:
Start: 07/31/05 End: 12/31/13 Due: 12/31/14

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02406144 Org: User:
Start: 11/30/14 End: 11/30/17 Due: 11/30/18

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT04802356 Org: User:
Start: 04/07/21 End: 07/31/25 Due: 07/31/26

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Phase: N/A Priority: Normal
NCT ID: NCT01376427 Org: User:
Start: 01/31/07 End: 12/31/22 Due: 12/31/23

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Phase: N/A Priority: Normal
NCT ID: NCT05558319 Org: User:
Start: 10/31/22 End: 04/30/29 Due: 04/30/30

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Phase: N/A Priority: Normal
NCT ID: NCT03523429 Org: User:
Start: 06/30/18 End: 03/09/22 Due: 03/09/23

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00488709 Org: User:
Start: 05/31/03 End: 04/30/07 Due: 04/30/08

Glivec in Ph Positive Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00388895 Org: User:
Start: 06/30/02 End: 10/31/07 Due: 10/31/08

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Phase: N/A Priority: Normal
NCT ID: NCT05049473 Org: User:
Start: 01/31/14 End: 01/31/24 Due: 01/31/25

CML Treated With Bosutinib After Relapse

Phase: N/A Priority: Normal
NCT ID: NCT02445742 Org: User:
Start: 05/31/15 End: 06/27/19 Due: 06/27/20

LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

Phase: N/A Priority: Normal
NCT ID: NCT00466258 Org: User:
Start: 10/31/06 End: 11/30/09 Due: 11/30/10

Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis

Phase: N/A Priority: Normal
NCT ID: NCT00391014 Org: User:
Start: 01/31/06 End: 04/30/09 Due: 04/30/10

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02415413 Org: User:
Start: 05/31/15 End: 06/30/27 Due: 06/30/28

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03742323 Org: User:
Start: 07/01/18 End: 06/02/20 Due: 06/02/21

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase: N/A Priority: Normal
NCT ID: NCT00526305 Org: User:
Start: 01/31/00 End: 04/30/05 Due: 04/30/06

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Phase: N/A Priority: Normal
NCT ID: NCT06282978 Org: User:
Start: 11/23/23 End: 12/31/29 Due: 12/31/30

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT03477643 Org: User:
Start: 04/27/18 End: 07/14/20 Due: 07/14/21

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Phase: N/A Priority: Normal
NCT ID: NCT05218603 Org: User:
Start: 11/30/21 End: 11/06/25 Due: 11/06/26

Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)

Phase: N/A Priority: Normal
NCT ID: NCT01366898 Org: User:
Start: 06/30/07 End: 12/31/22 Due: 12/31/23

Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00388193 Org: User:
Start: 08/31/06 End: 12/31/13 Due: 12/31/14

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Phase: N/A Priority: Normal
NCT ID: NCT01802450 Org: User:
Start: 03/31/13 End: 12/31/16 Due: 12/31/17

Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

Phase: N/A Priority: Normal
NCT ID: NCT01084837 Org: User:
Start: 03/31/10 End: 12/31/13 Due: 12/31/14

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Phase: N/A Priority: Normal
NCT ID: NCT04179929 Org: User:
Start: 11/25/19 End: 02/28/27 Due: 02/28/28

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Phase: N/A Priority: Normal
NCT ID: NCT01194791 Org: User:
Start: 10/31/10 End: 12/31/16 Due: 12/31/17